Is CJC-1295 FDA-approved?
No. FDA's review of the related substances says none is a component of an FDA-approved drug. A familiar name doesn't supply that approval.
You may also see old claims about Category 2, FDA's group for substances with safety concerns. On FDA's page current as of April 22, 2026, CJC-1295 appears among substances nominated but withdrawn. That means the requests were taken back, not that FDA cleared it for compounding. The page gives no individual withdrawal date and still lists safety concerns.
For ordinary pharmacy compounding, the ingredient needs an official quality standard, a place in an approved drug or a place on the 503A bulks list. CJC-1295 meets none of those ingredient routes in the FDA records discussed here. A prescription doesn't turn that into clearance.
Is no DAC just the shorter-acting version of the same thing?
FDA calls the forms different active ingredients that can't be swapped. DAC means drug affinity complex: an added part that attaches to albumin, a blood protein, and helps the peptide stay around longer.
The form without DAC lacks that part. FDA's December 2024 review found no human studies of the no-DAC forms, so I don't attach the long-acting study's timing number to them. The half-life page keeps that missing answer visible.
Do higher hormone levels mean better sleep or recovery?
The early human study showed higher growth hormone and IGF-1, a growth factor affected by growth hormone. It didn't measure better sleep or faster recovery. Those benefits need their own evidence.
People in research-use communities describe those changes, but the reports are anecdotal, not clinical evidence. I can understand the hope without calling it a demonstrated result. The effects notes put the finding and the hope beside each other.
Does a reassuring early study settle safety?
No. A small study can't establish years of safety. FDA's wider review discusses faster heart rate, widening blood vessels and immune concerns, where the body may react to the peptide as something foreign.
It also raises possible risks from sustained hormone elevation, including blood-sugar changes and fluid retention. Long-term safety remains unknown. That isn't a prediction about every reader; it's a limit on what the evidence can tell us.
I'd bring both the hoped-for change and those gaps into a clinical conversation. The original concern still deserves attention, even if CJC-1295 turns out to be the wrong direction.